What is the equity of AC Immune this year?
AC Immune has equity of 112.27 M CHF this year.
AC Immune Equity 2025
AC Immune Equity
112.27 M CHF
Ticker
ACIU
ISIN
CH0329023102
WKN
A2AR5F
In 2025, AC Immune's equity was 112.27 M CHF, a -30.11% increase from the 160.64 M CHF equity in the previous year.
AC Immune Aktienanalyse
What does AC Immune do?
AC Immune SA is a biopharmaceutical company specializing in the discovery and development of drugs for the treatment of neurodegenerative diseases as well as cancer. It was founded in 2003 by a group of leading researchers in the field of neurodegeneration and is based in Lausanne, Switzerland. The company has established itself as one of the leading companies in Alzheimer's research in recent years. AC Immune SA focuses on developing drugs targeting protein aggregation that occurs in Alzheimer's and other neurodegenerative diseases in the brain. It has developed an innovative platform technology that allows for the development of specific antibodies that selectively bind to certain toxic or disease-causing proteins. AC Immune has developed a variety of proprietary technologies and platforms that enable rapid and efficient identification, testing, and optimization of therapeutics. Its main products are antibodies that therapeutically target Alzheimer's, Parkinson's, TAU, and Alpha-Synuclein prions. These antibodies that target protein disease-related plaques help slow disease progression and alleviate symptoms. AC Immune has also developed and tested drugs for cancer treatment. The company operates in two main segments: research and development, as well as clinical studies. It has a strong pipeline of products in development that are in various stages of clinical trials. These products target various diseases including Alzheimer's, Parkinson's, advanced stage cancer, prion diseases, neurodegenerative sanatoria, and Down syndrome. AC Immune SA collaborates closely with various academic research institutions, biotechnology companies, pharmaceutical companies, and government agencies to bring innovative therapies to market. It has formed numerous partnerships and alliances with renowned partners in the pharmaceutical, biotech, and life science industries to accelerate the translation of promising therapeutic approaches into clinical applications. Recently, AC Immune SA announced a partnership with Genentech, a leading company in the development of biological therapies and diagnostic procedures. The two companies are working together to develop treatments for Alzheimer's and several other neurodegenerative diseases. Another example is the collaboration with Eli Lilly and Company for the use of ACI-3024 in the fight against tauopathies, including Alzheimer's disease and progressive supranuclear palsy. AC Immune SA has a strong foundation in scientific research and development, as well as in the commercialization of therapeutics. The company has a comprehensive product pipeline aimed at developing innovative therapy options for patients with neurodegenerative diseases and cancer. With its proprietary technology platform and partnerships with leading companies in the biotech and pharmaceutical industries, AC Immune SA has great potential to make significant advances in the development of therapies that improve patients' lives and enhance their quality of life. AC Immune ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing AC Immune's Equity
AC Immune's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AC Immune's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating AC Immune's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
AC Immune's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in AC Immune’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about AC Immune stock
What was the equity of AC Immune compared to the previous year?
The equity of AC Immune has increased/decreased by -30.11% decreased compared to the previous year.
What impact does a high equity have on investors of AC Immune?
A high equity is advantageous for investors of AC Immune as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of AC Immune?
A low equity can be a risk for investors of AC Immune, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of AC Immune affect the company?
An increase in equity of AC Immune can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of AC Immune affect the company?
A reduction in equity of AC Immune can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of AC Immune?
Some factors that can affect the equity of AC Immune include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of AC Immune so important for investors?
The equity of AC Immune is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can AC Immune take to change the equity?
To change equity, AC Immune can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does AC Immune pay?
Over the past 12 months, AC Immune paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AC Immune is expected to pay a dividend of 0 CHF.
What is the dividend yield of AC Immune?
The current dividend yield of AC Immune is .
When does AC Immune pay dividends?
AC Immune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AC Immune?
AC Immune paid dividends every year for the past 0 years.
What is the dividend of AC Immune?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is AC Immune located?
AC Immune is assigned to the 'Health' sector.
Wann musste ich die Aktien von AC Immune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AC Immune from 8/21/2025 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 8/21/2025.
When did AC Immune pay the last dividend?
The last dividend was paid out on 8/21/2025.
What was the dividend of AC Immune in the year 2024?
In the year 2024, AC Immune distributed 0 CHF as dividends.
In which currency does AC Immune pay out the dividend?
The dividends of AC Immune are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AC Immune
Our stock analysis for AC Immune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AC Immune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
